AzTrials
AzTrials

Celiac DiseaseNCT04349904

Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation

An observational study of Celiac Disease, run by King's College Hospital NHS Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There are no agreed endoscopic signs for the diagnosis of villous atrophy(VA) in coeliac disease(CD), necessitating biopsies and for both diagnosis and exclusion. Here we evaluated the role of near focus Narrow Band Imaging(NF-NBI) for the assessment of villous architecture in suspected CD with development and further… Read more about this study

Who is it for?
Any age
Conditions the study is for
Celiac Disease
What is being tested?
Near-Focus Narrow Band Imaging
How many people
100 participants
Where
1 siteUnited Kingdom
Study dates
6 Sep 2017to 3 Feb 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Child, Adult, Older adult

Study population: Consecutive patients attending the gastroenterology department requiring gastroscopy and duodenal biopsy to evaluate Villous Atrophy (VA) were approached for recruitment. All patients were recruited who satisfied British Society of Gastroenterology (BSG) criteria for the investigation of suspected Coeliac Disease (CD): positive coeliac serology, iron deficiency anaemia, weight loss, bloating, diarrhoea

Who may be able to join

  • Adult patients 18-90 years old
  • Retaining capacity and medically fit for gastroscopy
  • Requiring gastroscopy by current BSG guidelines for the investigation of anaemia or symptoms to suggest CD or positive serology.
  • Assessment of CD

Who cannot join

  • Outside inclusion age range
  • Unable to give informed consent
  • Clinical indication not satisfying inclusion criteria

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • King's College Hospital NHS Foundation Trust

    London, SE5 9RS

Other trials in United Kingdom

About this study

Official title: Near-Focus Narrow Band Imaging Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation

There are no agreed endoscopic signs for the diagnosis of villous atrophy(VA) in coeliac disease(CD), necessitating biopsies and for both diagnosis and exclusion. Here we evaluated the role of near focus Narrow Band Imaging(NF-NBI) for the assessment of villous architecture in suspected CD with development and further validation of a novel NF-NBI classification.

Read the detailed description

Coeliac disease (CD) is an autoimmune condition by the exposure to gluten in patients who are genetically susceptible. The global prevalence is thought to be 1%, and incidence rate of CD in the UK is approximately 13.8 per 100,000 person-years with greater than fourfold increase in incidence over the past two decades [1]. CD has variable clinical presentations including iron deficiency anaemia, diarrhoea, bloating, weight loss, osteoporosis, rash and rarely lymphoma. The ingestion of gluten triggers an immune response with the production of antibodies and an inflammatory destruction of small bowel (duodenal) mucosa (villous atrophy). The degree of villous atrophy is categorised based on duodenal biopsy analysis according to the Marsh classification [2]. Serological testing for antibody formation has varying sensitivity and specificity for CD with extent of villous damage [3]. At present the diagnosis of CD required confirmation on histopathological analysis of duodenal biopsy [4]. The British Society of Gastroenterology (BSG) requires the investigation of CD in all patients with iron deficiency anaemia as well as other symptoms above suggestive of CD [5]. Gastroscopy and duodenal biopsies are the current gold standard for exclusion or confirmation of CD [6]. Examination with standard white light endoscopy (WLE) can reveal patchy redness (erythema) of the small bowel mucosa and possibly appearance of flattening of the duodenal villi however due to limited sensitivity especially in milder cases of villous distortion and atrophy, biopsy is warranted [7]. Owing to this patchy nature of villous atrophy, orientation of biopsy is also imperative for accurate diagnosis of CD including biopsies from the duodenal bulb as well as the second part of the duodenum [8,9]. Although biopsy is the gold standard for diagnosis of CD, it is limited by inadequate quality and orientation of sampling contributing to false negative [10]. Various endoscopic imaging techniques have been studied for the diagnosis of CD by assessment of villous architecture. The water immersion technique involves filling the lumen of the duodenum with water has shown promising sensitivity and specificity for the diagnosis of CD. Further study to assess reproducibility are warranted [11,12]. Magnification endoscopy has demonstrated reasonable positive and negative predictive value with a fair degree of reproducibility within the remit of preliminary data [13]. The addition of agents to enhance villous architecture during endoscopic examination such a water soluble blue dye spray (chromendoscopy) or ascetic acid have been assessed. Chromendoscopy has shown promising sensitivity and specificity for CD, however it has not been consistently demonstrated to be superior to WLE alone and no further benefit achieved when combining chromendoscopy to magnification endoscopy [14,15]. Furthermore, chromendoscopy is limited by operator technical ability in achieving a uniform coating of dye, interpretation and prolongs time and cost [16]. The addition of ascetic acid increased sensitivity for detecting villous atrophy and demonstrating the patchy nature of this to aid target biopsy but there is insufficient evidence to support the use of this for endoscopic diagnosis of CD alone [17]. Preliminary data for digital imaging technology; virtual chromendoscopy provided by Fujinon Intelligent Chromo Endoscopy (FICE) and i-scan developed by Pentax Medical, Japan have been conducted for the diagnoses of CD. FICE with magnification has shown 100% accuracy for evaluating villous patterns and i-scan for the diagnosis of total villous atrophy using I-scan but studies demonstrating reproduction of this have not been conducted [18,19]. Narrow Band Imaging (NBI) provides an IEE technique unique to Olympus Medical Systems. NBI provides unique images based on penetrative properties of light in tissue which is directly proportional to wavelength with a use of a filter integral to the endoscope which is switched on using a button on the hand control at the time of examination. This filter produces two narrow bands at specific wavelengths; 415nm blue light and 540nm green light which is absorbed by superficial and deep mucosal vessels respectively. NBI provides a distinct contrast between vascular architecture and mucosa as NBI wavelength is reflected by mucosa but absorbed by blood vessels and has been shown to add diagnostic value in a variety of diagnostic settings most notably in the distinction between neoplastic and non-neoplastic lesions of the gastrointestinal tract [20]. It is the distortion of the villous vascular pattern as seen with varying degrees of villous atrophy that has the potential of making an optical diagnosis of coeliac disease even in its early stages, obviating the need for routine biopsy [9]. Clear endoscopic images of villous atrophy in comparison to healthy villi have been published using high resolution narrow band imaging in known CD [21]. Preliminary study of magnification in combination with NBI has shown feasibility for the detection of both total villous and partial villous atrophy, superiority to WLE with observer agreement [22,23]. A prospective observational study assessing the use of narrow band imaging in assessing duodenal villous atrophy in a variety of clinical scenarios has been performed however patients with a known diagnosis of coeliac disease were excluded [24,25]. These studies are limited by small sample size with only preliminary data for inter-observer variation. Dual focus NBI is a unique imaging system to Olympus endoscopic technology involving two-stage optical system operated by a single push of a button on the controller. The 'near' mode provides higher resolution power compared to previous NBI generations and holds enhanced brightness and contrast ability. This study will assess the ability of dual focus NBI for the endoscopic diagnosis of coeliac disease. To date there are no large prospective observational cohort studies evaluating conventional endoscopy and dual focus narrow band imaging for the endoscopic diagnosis and assessment of coeliac disease. Additionally there is limited data on inter-observer variation using NBI across degrees of endoscopic expertise; an important consideration when translating research findings to wide clinical practice. Additionally, NBI is readily available in most UK endoscopy centres making its implementation in practice relatively straightforward and of limited financial implication.

Conditions
Celiac Disease
Being tested
Near-Focus Narrow Band Imaging
Medical subject headings
Celiac Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Near-Focus Narrow Band ImagingDiagnostic test

    High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To evaluate the diagnostic performance of Near-Focus NBI (NF-NBI) for the diagnosis and assessment of Villous Atrophy (VA) in suspected Coeliac Disease (CD).

    Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Accuracy

    Measured: 6 weeks post endoscopy and duodenal biopsy

Secondary outcomes (1)
  1. To develop and initially validate a novel NF-NBI classification of VA

    Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Accuracy, Inter-observer agreement

    Measured: 3 months post completion of data collection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2020
  2. Study start6 Sep 2017
  3. Primary completion26 Jul 2018
  4. Study completion3 Feb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04349904
Sponsor's protocol ID
222807
Status last verified
Apr 2020
First submitted
14 Apr 2020
Last updated
16 Apr 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Shared upon request

Publications

  • West J, Fleming KM, Tata LJ, Card TR, Crooks CJ. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol. 2014 May;109(5):757-68. doi: 10.1038/ajg.2014.55. Epub 2014 Mar 25.

    PubMed 24667576
  • Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology. 1992 Jan;102(1):330-54.

    PubMed 1727768
  • Rostom A, Dube C, Cranney A, Saloojee N, Sy R, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, McNeil J, Moher D, Mack D, Patel D. Celiac disease. Evid Rep Technol Assess (Summ). 2004 Jun;(104):1-6. No abstract available.

    PubMed 15346868
  • Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011 Oct;60(10):1309-16. doi: 10.1136/gut.2010.228874. Epub 2011 May 11.

    PubMed 21561874
  • Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA; American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013 May;108(5):656-76; quiz 677. doi: 10.1038/ajg.2013.79. Epub 2013 Apr 23.

    PubMed 23609613
  • Dickey W. Endoscopic markers for celiac disease. Nat Clin Pract Gastroenterol Hepatol. 2006 Oct;3(10):546-51. doi: 10.1038/ncpgasthep0601.

    PubMed 17008924
  • Hopper AD, Cross SS, Sanders DS. Patchy villous atrophy in adult patients with suspected gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate? Endoscopy. 2008 Mar;40(3):219-24. doi: 10.1055/s-2007-995361. Epub 2008 Dec 5.

    PubMed 18058655
  • Cammarota G, Cesaro P, Martino A, Zuccala G, Cianci R, Nista E, Larocca LM, Vecchio FM, Gasbarrini A, Gasbarrini G. High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic approach in diagnosing coeliac disease. Aliment Pharmacol Ther. 2006 Jan 1;23(1):61-9. doi: 10.1111/j.1365-2036.2006.02732.x.

    PubMed 16393281
  • Vogelsang H, Hanel S, Steiner B, Oberhuber G. Diagnostic duodenal bulb biopsy in celiac disease. Endoscopy. 2001 Apr;33(4):336-40. doi: 10.1055/s-2001-13702.

    PubMed 11315895
  • Cammarota G, Pirozzi GA, Martino A, Zuccala G, Cianci R, Cuoco L, Ojetti V, Landriscina M, Montalto M, Vecchio FM, Gasbarrini G, Gasbarrini A. Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointest Endosc. 2004 Aug;60(2):223-8. doi: 10.1016/s0016-5107(04)01553-6.

    PubMed 15278049
  • Cammarota G, Cesaro P, La Mura R, Martino A, Cazzato A, Miele L, Lupascu A, Vecchio FM, Larocca LM, Grieco A, Gasbarrini G. Role of the "immersion technique" in diagnosing celiac disease with villous atrophy limited to the duodenal bulb. J Clin Gastroenterol. 2007 Jul;41(6):571-5. doi: 10.1097/01.mcg.0000225625.99415.c0.

    PubMed 17577113
  • Badreldin R, Barrett P, Wooff DA, Mansfield J, Yiannakou Y. How good is zoom endoscopy for assessment of villous atrophy in coeliac disease? Endoscopy. 2005 Oct;37(10):994-8. doi: 10.1055/s-2005-870245.

    PubMed 16189773
  • Niveloni S, Fiorini A, Dezi R, Pedreira S, Smecuol E, Vazquez H, Cabanne A, Boerr LA, Valero J, Kogan Z, Maurino E, Bai JC. Usefulness of videoduodenoscopy and vital dye staining as indicators of mucosal atrophy of celiac disease: assessment of interobserver agreement. Gastrointest Endosc. 1998 Mar;47(3):223-9. doi: 10.1016/s0016-5107(98)70317-7.

    PubMed 9580349
  • Kiesslich R, Mergener K, Naumann C, Hahn M, Jung M, Koehler HH, Nafe B, Kanzler S, Galle PR. Value of chromoendoscopy and magnification endoscopy in the evaluation of duodenal abnormalities: a prospective, randomized comparison. Endoscopy. 2003 Jul;35(7):559-63. doi: 10.1055/s-2003-40240.

    PubMed 12822089
  • Siegel LM, Stevens PD, Lightdale CJ, Green PH, Goodman S, Garcia-Carrasquillo RJ, Rotterdam H. Combined magnification endoscopy with chromoendoscopy in the evaluation of patients with suspected malabsorption. Gastrointest Endosc. 1997 Sep;46(3):226-30. doi: 10.1016/s0016-5107(97)70091-9.

    PubMed 9378209

Questions about this trial

What is this clinical trial studying?

An observational study of Celiac Disease, run by King's College Hospital NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To evaluate the diagnostic performance of Near-Focus NBI (NF-NBI) for the diagnosis and assessment of Villous Atrophy (VA) in suspected Coeliac Disease (CD). (time frame: 6 weeks post endoscopy and duodenal biopsy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04349904, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in